# A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery

> **NCT07676890** · PHASE1 · RECRUITING · sponsor: **West China Hospital** · enrollment: 9 (estimated)

## Conditions studied

- Ovarian Cancer
- mRNA Vaccine

## Interventions

- **DRUG:** Low Dose NeoOVIV
- **DRUG:** Medium dose NeoOVIV
- **DRUG:** High dose NeoOVIV

## Key facts

- **NCT ID:** NCT07676890
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-10
- **Primary completion:** 2028-05-30
- **Final completion:** 2028-05-30
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07676890

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07676890, "A Single-Arm, Open-Label, Prospective Study Evaluating the Safety, Tolerability, and Immunogenicity of the NeoOVIV Vaccine in Patients With Ovarian Cancer After Surgery". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07676890. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*